The Geriatric Cancer Patient

Yancik R. , Ries L.A.G. . Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000; 14: 17–23.

American Cancer Society. Cancer Facts & Figures 2000. Atlanta, Ga: American Cancer Society; 2000.

Lyman G.H. . Cancer care in the elderly. Cancer Control. 1998; 5: 347–354.

Kampmann J.P. , Mølholm Hansen J. . Glomerular filtration rate and creatinine clearance. Br J Clin Pharmacol. 1981; 12: 7–14.

Shemesh O. , Golbetz H. , Kriss J.P. , Myers B.D. . Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985; 28: 830–838.

Cockcroft D.W. , Gault M.H. . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31–41.

Balducci L. , Extermann M. . Management of cancer in the older person: a practical approach. Oncologist. 2000; 5: 224–237.

Lancet J.E. , Willman C.L. , Bennett J.M. . Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am. 2000; 14: 251–267.

Balducci L. , Extermann M. . Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am. 2000; 14: 1–16.

Bonadonna G. , Valagussa P. , Moliterni A. , Zambetti M. , Brambilla C. . Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 332: 901–906.

Budman D.R. , Berry D.A. , Cirrincione C.T. . Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998; 90: 1205–1211.

Kwak L.W. , Halpern J. , Olshen R.A. , Horning S.J. . Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990; 8: 963–977.

Epelbaum R. , Faraggi D. , Ben-Arie Y. . Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables. Cancer. 1990; 66: 1124–1129.

Lepage E. , Gisselbrecht C. , Haioun C. . Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. Ann Oncol. 1993; 4: 651–656.

Crawford J. , Ozer H. , Stoller R. . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991; 325: 164–170.

Trillet-Lenoir V. , Green J. , Manegold C. . Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer. 1993; 29A: 319–324.

de Graaf H. , Willemse P.H.B. , Bong S.B. . Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology. 1996; 53: 289–294.

Pettengell R. , Gurney H. , Radford J.A. . Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992; 80: 1430–1436.

Crivellari D. , Bonetti M. , Castiglione-Gertsch M. . Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group trial VII. J Clin Oncol. 2000; 18: 1412–1422.

Dees E.C. , O'Reilly S. , Goodman S.N. . A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000; 18: 521–529.

Begg C.B. , Elson P.J. , Carbone P.P. . A study of excess hematologic toxicity in elderly patients treated on cancer chemotherapy protocols. In: Yancik R. , Yates J.W. , eds. Cancer in the Elderly: Approaches to Early Detection and Treatment. New York, NY: Springer Publ Co; 1989: 149–163.

Chatta G.S. , Dale D.C. . Aging and haemopoiesis: implications for treatment with haemopoietic growth factors. Drugs Aging. 1996; 9: 37–47.

Lipschitz D.A. . Age-related declines in hematopoietic reserve capacity. Semin Oncol. 1995; 22(suppl 1): 3–5.

Gómez H. , Mas L. , Casanova L. . Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol. 1998; 16: 2352–2358.

Dixon D.O. , Neilan B. , Jones S.E. . Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986; 4: 295–305.

Gaynor E.R. , Dahlberg S. , Fisher R.I. . Factors affecting reduced survival of the elderly with intermediate and high grade lymphoma: an analysis of SWOG-8516 (INT 0067)—the National High Priority Lymphoma Study: a randomized comparison of CHOP vs m-BACOD vs ProMACE-CytaBOM vs MACOP-B. Proc Am Soc Clin Oncol. 1994; 13. Abstract 1250.

Tirelli U. , Zagonel V. , Errante D. , Fratino L. , Monfardini S. . Treatment of non-Hodgkin's lymphoma in the elderly: an update. Hematol Oncol. 1998; 16: 1–13.

Zinzani P.L. , Storti S. , Zaccaria A. . Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood. 1999; 94: 33–38.

Gómez H. , Hidalgo M. , Casanova L. . Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998; 16: 2065–2069.

Guerci A. , Lederlin P. , Reyes F. . Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Ann Oncol. 1996; 7: 966–969.

Bjorkholm M. , Osby E. , Hagberg H. . Randomized trial of r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP treatment of elderly patients with aggressive non-Hodgkin's lymphoma. Blood. 1999; 94: 599a. Abstract 2665.

Zagonel V. , Babare R. , Merola M.C. . Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol. 1994; 5(suppl 2): 127–132.

Liu Yin J.A. , Johnson P.R.E. , Davies J.M. , Flanagan N.G. , Gorst D.W. , Lewis M.J. . Mitoxantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukaemia. Br J Haematol. 1991; 79: 415–420.

Rowe J.M. , Andersen J.W. , Mazza J.J. . A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995; 86: 457–462.

Stone R.M. , Berg D.T. , George S.L. . Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995; 332: 1671–1677.

Dombret H. , Chastang C. , Fenaux P. . A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med. 1995; 332: 1678–1683.

Moore J.O. , Dodge R.K. , Amrein P.C. . Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997; 89: 780–788.

Heil G. , Hoelzer D. , Sanz M.A. . A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood. 1997; 90: 4710–4718.

Kimmick G.G. , Balducci L. . Breast cancer and aging: clinical interactions. Hematol Oncol Clin North Am. 2000; 14: 213–234.

Yancik R. , Ries L.A. . Cancer in older persons: magnitude of the problem—how do we apply what we know? In: Balducci L. , Lyman G.H. , Ershler W.B. , eds. Comprehensive Geriatric Oncology. Amsterdam; The Netherlands: Harwood Academic Publishers; 1998: 95–103.

Lyman G.H. , Lyman S. , Balducci L. . Age and the risk of breast cancer recurrence. Cancer Control. 1996; 3: 421.

Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998; 352: 930–942.

Extermann M. , Balducci L. , Lyman G.H. . What threshold for adjuvant chemotherapy in older breast cancer patients? J Clin Oncol. 2000; 18: 1709–1717.

Colleoni M. , Price K.N. , Castiglione-Gertsch M. , Gelber R.D. , Coates A.S. , Goldhirsh A. . Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Lancet. 1999; 354: 130–131.

Shank WA Jr , Balducci L. . Recombinant hemopoietic growth factors: comparative hemopoietic response in younger and older subjects. J Am Geriatr Soc. 1992; 40: 151–154.

Cohen A.M. , Minsky B.D. , Schilsky R.L. . Cancer of the colon. In: DeVita V.T. , Hellman S. , Rosenberg S.A. , eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven Publishers. 1997: 1144–1197.

Sargent D. , Goldberg R. , MacDonald J. . Adjuvant chemotherapy for colon cancer (CC) is beneficial without significantly increased toxicity in elderly patients (pts): results from a 3351-pt meta-analysis. Proc Am Soc Clin Oncol. 2000; 19. Abstract 933.

Ginsberg R.J. , Vokes E.E. , Raben A. . Non-small cell lung cancer. In: DeVita V.T. , Hellman S. , Rosenberg S.A. , eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven Publishers. 1997: 858–911.

Langer C. , Manola J. , Bernardo P. . Advanced age alone does not compromise outcome in fit non-small cell lung cancer (NSCLC) patients (pts) receiving platinum (DDP)-based therapy (TX): implications of ECOG 5592. Proc Am Soc Clin Oncol. 1999; 17. Abstract 1912.

Rosvold E. , Langer C.J. , McAleer C. , Zipin H. , Bonjo C. , Ozols R. . Advancing age does not exacerbate toxicity or compromise outcome in non-small cell lung cancer (NSCLC) patients (pts) receiving paclitaxel-carboplatin (P-C). Proc Am Soc Clin Oncol. 1999; 17. Abstract 1846.

Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999; 91: 66–72.

Smith T.J. , Hillner B.E. , Neighbors D.M. , McSorley P.A. , Le Chevalier T. . Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol. 1995; 13: 2166–2173.

Martins S.J. , Pereira J.R. , Ikari F.K. . Chemotherapy (CT) with cisplatin and vinorelbine for elderly non-small-cell lung cancer (NSCLC) patients. Proc Am Soc Clin Oncol. 1999; 17. Abstract 1804.

Ozer H. , Armitage Jo , Bennett C.L. . 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol. 2000; 18: 3558–3585.

Lyman G.H. , Kuderer N. , Greene J. , Balducci L. . The economics of febrile neutropenia: implications for the use of colony-stimulating factors. Eur J Cancer. 1998; 34: 1857–1864.

Chatta G.S. , Price T.H. , Stratton J.R. , Dale D.C. . Aging and marrow neutrophil reserves. J Am Geriatr Soc. 1994; 42: 77–81.

Jacobson J.O. , Grossbard M. , Shulman L.N. . CHOP chemotherapy with G-CSF in elderly patients with intermediate grade lymphoma (IGL): full dose intensity is possible. Proc Am Soc Clin Oncol. 1988; 17. Abstract 41.

Katz S. , Ford A.B. , Moskowitz R.W. . Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963; 185: 94–99.

Lawton M.P. . Scales to measure competence in everyday activities. Psychopharmacol Bull. 1988; 24: 609–614, 789-791.

Zubrod C.G. , Schneiderman M. , Frei E III . Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chron Dis. 1960; 11: 7–33.

Karnofsky D.A. , Abelmann W.H. , Craver L.F. , Burchenal J.H. . The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948; 1: 634–656.

Extermann M. , Overcash J. , Lyman G.H. , Parr J. , Balducci L. . Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16: 1582–1587.

Charlson M.E. , Pompei P. , Ales K. , MacKenzie C.R. . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987; 40: 373–383.

Miller M.D. , Paradis C.F. , Houck P.R. . Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992; 41: 237–248.

Folstein M.F. , Folstein S.E. , McHugh P.R. . Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12: 189–198.

Sheikh J.J. , Yesavage J.A. . Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink T.L. , ed. Clinical Gerontology: A Guide to Assessment and Intervention. New York, NY: Haworth Press; 1986: 165–173.

Beck A.T. , Ward C.H. , Mendelson M. , Mock J. , Erbaugh J. . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4: 53–63.

Balducci L. , Stanta G. . Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am. 2000; 14: 235–250.

Hamerman D. . Toward an understanding of frailty. Ann Intern Med. 1999; 130: 945–950.

Balducci L. , Yates J. . General guidelines for management of older patients with cancer. Oncology. 2000; 14: 221–227.

Gelman R.S. , Taylor SG IV . Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984; 2: 1404–1413.

Kintzel P.E. , Dorr R.T. . Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995; 21: 33–64.

Gurney H. . Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996; 14: 2590–2611.

Hutchins L.F. , Unger J.M. , Crowley J.J. , Coltman CA Jr , Albain K.S. . Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061–2067.

Kemeny M.M. , Muss H.B. , Kornblith A.B. , Peterson B. , Wheeler J. , Cohen H.J. . Barriers to participation of older women with breast cancer in clinical trials. Presented at: 36th Annual Meeting of the American Society of Clinical Oncology; May 20-23, 2000; New Orleans, La.

Chen C.I. , Skingley P. , Meyer R.M. . A comparison of elderly patients with aggressive histology lymphoma who were entered or not entered on to a randomized phase II trial. Leuk Lymphoma. 2000; 38: 327–334.

Mahoney T. , Kuo Y.H. , Topilow A. , Davis J.M. . Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg. 2000; 135: 182–185.

Peake M. . Elderly lung cancer patients in UK are undertreated. Presented at: 96th International Conference of the American Thoracic Society; May 5-10, 2000; Toronto, Ontario, Canada.

Goodwin J.S. , Samet J.M. , Hunt W.C. . Determinants of survival in older cancer patients. J Natl Cancer Inst. 1996; 88: 1031–1038.